drugset / Trial / NCT00344513

Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

NCT00344513

Phase 4 Completed 50000 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.

Timeline

Start
2002-12-16
Primary completion
Completion
2005-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified